|
|
IFNβ |
|
Vaxjo ID |
253 |
|
Vaccine Adjuvant Name |
IFNβ |
|
Alternative Names |
Type I Interferon beta |
|
Adjuvant VO ID |
VO_0005740
|
|
Description |
IFNβ is a type I interferon cytokine that enhances anti-tumor immune responses, particularly by promoting cross-priming of CD8⁺ T cells through dendritic cells. It's investigated here as a potent adjuvant in cancer vaccination strategies |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs) |
|
Structure |
Protein cytokine (~166 amino acids), signals via IFNAR1/IFNAR2 receptor complex. |
|
Preparation |
Recombinant IFNβ was either: Endogenously expressed by tumor cell lines (via viral transduction), or Injected as recombinant protein at 1×10⁵ IU per mouse during vaccination |
|
Dosage |
2.5×10⁶ irradiated tumor cells plus 1×10⁵ IU IFNβ intraperitoneally per vaccination in mice. |
|
Function |
Therapeutically, vaccination with IFNβ delayed tumor progression when compared to vaccination without IFN. When vaccinated in combination with anti-PD-L1 checkpoint blockade therapy (CPB), the inclusion of IFNβ associated with more mice experiencing complete regression and a trend in increased overall survival. This work demonstrates the potent adjuvant activity of IFNβ, highlighting its potential to enhance cancer vaccination strategies alone and in combination with CPB |
|
Safety |
Well-tolerated in mice |
| References |
Audsley et al., 2021: Audsley KM, Wagner T, Ta C, Newnes HV, Buzzai AC, Barnes SA, Wylie B, Armitage J, Kaisho T, Bosco A, McDonnell A, Cruickshank M, Fear VS, Foley B, Waithman J. IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies. Frontiers in immunology. 2021; 12; 735133. [PubMed: 34552594].
|
|
